Indaptus Therapeutics, Inc. (INDP)
AI stock analysis · as of Jun 5, 2026
Loading microstructure…
Indaptus Therapeutics (INDP) is no longer a functioning biotech — it has discontinued its Decoy20 immunotherapy program and effectively become a cash-burning shell controlled by a single investor (originally Lazar, now Yun Yao holding ~42M shares post-conversion) hunting for a reverse merger target. The core investment question is whether the post-Investment Transaction shell can identify and consummate a value-accretive reverse merger before cash runs out, against a backdrop of going-concern doubt, ~96% insider control, and catastrophic dilution already baked in.
valuationExpensive on any fundamental basis — P/B of 347x, zero revenue, -$20.8M net loss, and negative FCF yield; the $433M market cap appears to reflect a fully-diluted share count assumption that vastly exceeds the 2.24M legacy shares, making the headline market cap misleading and the equity effectively a lottery ticket on a reverse merger.
This analysis is from Jun 5, 2026. Want the latest on INDP, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Lazar/Yao transaction injected $6M of fresh capital (closed Dec 23, 2025) plus prior ATM (~$2.3M) and SEPA (~$1.74M) raises, giving the shell some optionality to pursue a reverse merger
- · Shell vehicles with clean Nasdaq listings can re-rate sharply when a credible operating-business target is announced — historical precedent for 2-5x moves on deal announcement
- · Tiny share count (2.24M shares pre-conversion) and high insider ownership (96.9%) means very thin float, which can amplify upside on any positive headline
- · Preclinical Decoy20 data showing synergy with checkpoint inhibitors and chemo retains residual licensing/partnership optionality, however remote
- · NOL carryforwards (currently fully reserved) could become valuable to an acquiring operating business in a reverse merger structure
Bear case
- · Explicit going-concern qualification with only $1.5M cash at Q1 2026 — runway is measured in months, not quarters
- · Catastrophic dilution already structured: Lazar preferred converts to 111M shares vs. 2.24M outstanding, taking insiders to ~96.4% fully diluted and crushing existing common holders
- · Clinical pipeline fully discontinued — Decoy20 mono and combo trials halted with no plans to restart, eliminating fundamental biotech value
- · P/B of 347x against negative ROE of -931% and zero revenue is mathematically untethered from fundamentals
- · No identified reverse merger target; deal sourcing is speculative and Nasdaq compliance risk persists after a 1-for-28 reverse split in June 2025
- · 1.67M warrants repriced to $1.75 in Feb 2026 create additional overhang on any rally above that level
Catalysts
- · Announcement of a reverse merger target — the single largest binary event for the shell
- · Further dilutive financings or strip-out transactions tied to the Yao/Lazar control group
- · Nasdaq delisting notice or compliance action given sub-$10M market cap history and bid price concerns
- · Additional leadership changes following the recent CEO transition to Yun Yao
- · Short interest is negligible (0.05% of float, 1.09 days to cover) — no squeeze setup despite the speculative tape
Key risks
- · Going-concern failure / bankruptcy if no merger or financing materializes within ~2 quarters
- · Massive dilution from preferred conversion (111M shares) effectively eliminates minority shareholder economic interest
- · Controlling shareholder (Yao, ~42M shares) can direct any reverse merger on terms unfavorable to legacy common holders
- · Nasdaq delisting would collapse liquidity and any remaining shell premium
- · Warrant exercises at $1.75 cap upside on any rally
What to watch
- · Any 8-K disclosing a reverse merger target or LOI
- · Cash balance updates — Q1 2026 already at $1.5M, runway critical
- · Nasdaq deficiency notices on minimum bid price or market cap
- · Form 4 filings from Yun Yao or other insiders signaling control-group activity
- · Conversion of remaining preferred and warrant exercises that would flood the float
- · Key technical levels: $1.75 warrant strike (resistance) and $0.92 52-week low (support)
Key metrics
Price target rationale
Base case ($1.50) assumes continued dilution pressure and shell-status drift toward the $1.75 warrant strike absent a deal. Bull case ($5.00) reflects a credible reverse merger announcement triggering a re-rate, capped by 111M-share dilution overhang. Bear case ($0.40) reflects failure to consummate a deal, Nasdaq compliance action, or near-term insolvency taking the stock back toward 52-week lows ($0.92) and below as dilution fully prices in.
On Wall Street's view (mixed): No sell-side analyst coverage exists (target_mean/high/low all null, recommendation 'none'), which itself is telling — institutional research has abandoned the name. With no consensus to assess, the absence of coverage reinforces a cautious stance.
Latest filing (10-K)
Indaptus is a failed clinical-stage biotech that has abandoned its cancer immunotherapy program and handed control to a single investor for $6M, now functioning as a blank-check shell hunting for a reverse merger target while facing massive preferred stock dilution and going-concern risk.
Indaptus Therapeutics (INDP) is a clinical-stage biotechnology company that developed Decoy20, a systemically administered immunotherapy based on attenuated, killed Gram-negative bacteria designed to activate both innate and adaptive immune responses against cancer and viral infections. The company has no revenue and funds operations entirely through equity and debt financings. Following a December 2025 investment by David Lazar for $6 million in preferred stock, the company has effectively pivoted away from drug development and is now a shell-like entity seeking to acquire or invest in an operating business.
What the news says · neutral
INDP has seen sharp short-term price spikes (53.8% jump on June 4, a 12% gain in late December) driven almost entirely by speculative momentum and financing/strategic-option uncertainty rather than any fundamental catalyst. The underlying picture is deeply concerning: the company ended Q1 2026 with only $1.5M in cash, has cut R&D spending, and has issued explicit going-concern warnings about its cash runway. A significant leadership and ownership overhaul — including a CEO change led by Yun Yao (now holding ~42M shares after preferred conversion) and the departure of co-CEO David Lazar — adds further uncertainty about strategic direction. Insider losses and a thin, speculative news cycle suggest the stock's volatility reflects distress trading rather than genuine value creation.
This analysis is from Jun 5, 2026. Markets move. Get the current read on INDP and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.